Method of determining risk of arrythmia

An arrhythmia, risk technology, used in biological testing, measurement devices, material inspection products, etc., can solve problems such as limiting the flow and duration of MEA research

Inactive Publication Date: 2013-07-24
F HOFFMANN LA ROCHE & CO AG
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, technical limitations limit the throughput and duration of M

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method of determining risk of arrythmia
  • Method of determining risk of arrythmia
  • Method of determining risk of arrythmia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0092] method

[0093] Chemicals

[0094] In vitro reagents were purchased from Sigma Chemical Co. (St Louis MO).

[0095] method

[0096] cell culture. Thaw hiPSC-derived cardiomyocytes (iCells) from Cellular Dynamics International (CDI) in Plating Media (CDI) and grow at 2.2–2.7 × 10 per well 6 Densities of individual cells were plated as single cells on 0.1% gelatin (Sigma)-coated 6-well tissue culture plates (Corning). At 37°C, 7% CO 2 Cells were cultured for 3-5 days, after which they were re-plated onto 96-well cardio-e-plates (ACEA / Roche Applied Sciences) or microelectrode arrays (MEA, Multichannel Systems). After plating, the medium was changed every two days using Maintenance Media (CDI) (prewarmed to 37°C to minimize temperature shock to the cells).

[0097] overview

[0098] The new RTCA cardio system allows monitoring of cellular experiments over longer time frames and measures the contraction (beating) of cells in parallel. At each measurement time point...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a method of determining the risk of drug induced arrhythmia using stem cell derived cardiomyocytes in a high-throughput impedance or multi-electrode array assay.

Description

[0001] The present invention relates to methods for determining drug-induced arrhythmia risk using stem cell-derived cardiomyocytes using high-throughput impedance or multielectrode array assays. Background of the invention [0002] Drug-induced torsades de pointes (TdP), a life-threatening polymorphic ventricular tachyarrhythmia, has led to the withdrawal or withdrawal of many medications. Severe limitations ((Journal of Pharmacological and Toxicological Methods52:46-59, 2005). The usual cause of TdP is the repression of the inward rectifying potassium channel, hERG (the human or go-go related gene encoded by KCNH2), results in a prolonged QT interval. Currently, the standard approach is to screen drug candidates for hERG inhibition using non-cardiomyocyte cell lines that overexpress hERG. However, hERG screening is suboptimal because not all compounds that inhibit hERG channels Both cause QT prolongation or induce TdP (Cardiovascular Research 58:32-45, 2003).In addition, arr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N33/68
CPCG01N33/6887G01N2800/326C12N5/06G01N27/00G01N27/128G01N33/5061
Inventor R·阿布拉姆斯J·巴比亚兹E·乔郭亮K·L·科拉雅
Owner F HOFFMANN LA ROCHE & CO AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap